Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers
a case control study
Keywords:
Polyps, Tamoxifen, Menopause, Immunohistochemistry, Gynecology, EndometriumAbstract
BACKGROUND: Endometrial polyps are common in postmenopausal women, and the effect of tamoxifen use (a risk factor for endometrial polyps) on their pathogenesis is unclear. OBJECTIVES: To evaluate the expression of hormone receptors and markers for proliferation/apoptosis (Ki-67 and Bcl-2) in endometrial polyps in postmenopausal users and nonusers of tamoxifen. DESIGN AND SETTING: Cross-sectional analytical study in a tertiary-level academic hospital. METHODS: 46 women (14 tamoxifen users and 32 nonusers) with postmenopausal bleeding underwent hysteroscopic resection of endometrial polyps. Polyp samples were immunohistochemically assessed for detection of Ki-67, Bcl-2 and estrogen and progesterone receptors. RESULTS: Analysis on the glandular component of the polyps revealed progesterone receptor expression in the polyps of 96.9% of the nonusers of tamoxifen, and 92.3% of the tamoxifen users (P = 0.499). All polyps in nonusers and 92.3% of those in users were also positive for estrogen receptors (P = 0.295). Ki-67 was expressed in 75% of the polyps in the tamoxifen users and 82.8% of those in the nonusers. All endometrial polyps expressed Bcl-2. CONCLUSIONS: The immunohistochemical analysis on endometrial polyps demonstrated that, although tamoxifen is considered to be a risk factor for endometrial polyps, there were no significant differences in the expression of hormone receptors between users and nonusers of tamoxifen. There were no between-group differences in Ki-67 and Bcl-2 expression, and all patients displayed inhibition of apoptosis by Bcl-2, thus supporting the theory that polyps develop due to inhibition of apoptosis, and not through cell proliferation.
Downloads
References
McGurgan P, Taylor LJ, Duff SR, O’Donovan PJ. Are endometrial polyps from pre-menopausal women similar to post-menopausal women? An immunohistochemical comparison of endometrial polyps from pre and post-menopausal women. Maturitas. 2006;54(3):277-84. PMID: 16414216; doi: 10.1016/j.maturitas.2005.12.003.
Van Bogaert LJ. Clinicopathologic findings in endometrial polyps. Obstet Gynecol. 1988;71(5):771-3. PMID: 3357665.
Sant’Ana de Almeida EC, Nogueira AA, Candido dos Reis FJ, Zambelli Ramalho LN, Zucoloto S. Immunohistochemical expression of estrogen and progesterone receptors in endometrial polyps and adjacent endometrium in postmenopausal women. Maturitas. 2004;49(3):229-33. PMID: 15488351; doi: 10.1016/j.maturitas.2004.02.009.
Saidi MH, Sadler RK, Theis VD, et al. Comparison of sonography, sonohysterography, and hysteroscopy for evaluation of anormal uterine bleeding. J Ultrasound Med. 1997;16(9):587-91. PMID: 9321777; doi: 10.7863/jum.1997.16.9.587.
Reslová T, Tosner J, Resl M, Kugler R, Vávrová I. Endometrial polyps. A clinical study of 245 cases. Arch Gynecol Obstet. 1999;262(3-4):133-9. PMID: 10326632; doi: 10.1007/s004040050241.
Biron-Shental T, Tepper R, Fishman A, Shapira J, Cohen I. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol. 2003;90(2):382-6. PMID: 12893204; doi: 10.1016/S0090-8258(03)00276-2.
Schlesinger C, Kamoi S, Ascher SM, et al. Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups. Int J Gynecol Pathol. 1998;17(4):302-11. PMID: 9785130.
Ramondetta LM, Sherwood JB, Dunton JD, Palazzo JP. Endometrial cancer in polyps associated with tamoxifen use. Am J Obstet Gynecol. 1999;180(2 Pt 1):340-1. PMID: 9988797; doi: 10.1016/S0002-9378(99)70210-3.
Cohen I, Perel E, Flex D, et al. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients. J Clin Pathol. 1999;52(4):278-82. PMID: 10474520; doi: 10.1136/jcp.52.4.278.
Mittal K, Schwartz L, Goswami S, Demopoulos R. Estrogen and progesterone receptor expression on endometrial polyps. Int J Gynecol Pathol. 1996;15(4);345-8. PMID: 8886882.
Taylor LJ, Jackson TL, Reid JG, Duffy SR. The differential expression of oestrogen receptors, progesterone receptors, Bcl-2 and Ki67 in endometrial polyps. BJOG. 2003;110(9):794-8. PMID: 14511960; doi: 10.1111/j.1471-0528.2003.02098.x.
Koshiyama M, Yoshida M, Takemura M, et al. Immunohistochemical analysis of distribution of estrogen receptors and progesterone receptors in the postmenopausal endometrium. Acta Obstet Gynecol Scand. 1996;75(8):702-6. PMID: 8906001; doi: 10.3109/00016349609065730.
Maia H, Maltez A, Calmon LC, et al. Histopathology and steroid receptors in endometrial polyps of postmenopausal patients under hormone-replacement therapy. Gynaecological Endoscopy. 1998;7(5):267-72. doi: 10.1046/j.1365-2508.1998.00198.x.
Thijs I, Neven P, Van Hooff I, et al. Oestrogen and progesterone receptor expression in postmenopausal endometrial polyps and their surrounding endometrium. Eur J Cancer. 2000;36(4):108-9. doi: 10.1016/S0959-8049(00)00263-X.
Bergeron C. Effets sur l’endomètre des œstrogènes et des antiœstrogènes [Effect of estrogens and antiestrogens on the endometrium]. Gynecol Obstet Fertil. 2002;30(12):933-7. PMID: 12661281; doi: 10.1016/S1297-9589(02)00486-1.
Belisário MS, Vassallo J, Andrade LA, et al. The expression of the hormone receptors in the endometrium and endometrial polyps in postmenopausal women and its relationship to body mass index. Maturitas. 2006;53(1):114-8. PMID: 15894442; doi: 10.1016/j.maturitas.2005.03.013.
McGurgan P, Taylor LJ, Duffy SR, O’Donovan PJ. Does tamoxifen therapy affect the hormone receptor expression and cell proliferation indices of endometrial polyps? An immunohistochemical comparison of endometrial polyps from postmenopausal women exposed and not exposed to tamoxifen. Maturitas. 2006;54(3):252-9. PMID: 16413707; doi: 10.1016/j.maturitas.2005.11.007.
Vinatier D, Dufour P, Subtil D. Apoptosis: a programmed cell death involved in ovarian and uterine physiology. Eur J Obstet Gynecol Reprod Biol. 1996;67(2):85-102. PMID: 8841795; doi: 10.1016/0301-2115(96)02467-0.
Morsi HM, Leers MP, Jager W, et al. The patterns of expression of an apoptosis-related CK18 neoepitope, the bcl-2 protooncogene, and the Ki-67 proliferation marker in normal, hyperplasic and malignant endometrium. Int J Gynecol Pathol. 2000;19(2):118-26. PMID: 10782407.
Risberg B, Karlsson K, Abeler V, et al. Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and hystogenetic implications. Int J Gynecol Pathol. 2002;21(2):155-60. PMID: 11917225.
